[HTML] sciencedirect.com

[HTML][HTML] Cost-utility analysis of apixaban versus warfarin in atrial fibrillation patients with chronic kidney disease

SM Altawalbeh, OY Alshogran, KJ Smith - Value in Health, 2018 - Elsevier
Background Warfarin use for stroke prevention in atrial fibrillation (AF) patients with chronic
kidney disease is debated. Apixaban was shown to be safer than warfarin, with superior …
被引用次数：13 相关文章

Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease.

SM Altawalbeh, OY Alshogran… - … in Health: the Journal of the …, 2018 - europepmc.org
Background Warfarin use for stroke prevention in atrial fibrillation (AF) patients with chronic
kidney disease is debated. Apixaban was shown to be safer than warfarin, with superior …

Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease

SM Altawalbeh, OY Alshogran, KJ Smith - Value in Health, 2018 - valueinhealthjournal.com
Background Warfarin use for stroke prevention in atrial fibrillation (AF) patients with chronic
kidney disease is debated. Apixaban was shown to be safer than warfarin, with superior …

Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease

SM Altawalbeh, OY Alshogran… - Value in health: the …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Warfarin use for stroke prevention in atrial fibrillation (AF) patients with chronic
kidney disease is debated. Apixaban was shown to be safer than warfarin, with superior …

Cost Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease

SM Altawalbeh, OY Alshogran, KJ Smith - valueinhealthjournal.com
Supplementary Material Title: Cost Utility Analysis of Apixaban versus Warfarin in Atrial
Fibrillation Patients With Chronic Kidney Disease Journal: Value in Health Shoroq M. Altawalbeh …